Terms: = Prostate cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
140 results:
1. DB-1310, an ADC comprised of a novel anti-her3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of her3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
2. erbb3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive prostate cancer and is Associated with a Unique AR Activity Signature.
Vellky JE; Kirkpatrick BJ; Gutgesell LC; Morales M; Brown RM; Wu Y; Maienschein-Cline M; Notardonato LD; Weinfeld MS; Nguyen RH; Brister E; Sverdlov M; Liu L; Xu Z; Kregel S; Nonn L; Vander Griend DJ; Reizine NM
Clin Cancer Res; 2024 Apr; 30(8):1530-1543. PubMed ID: 38306015
[TBL] [Abstract] [Full Text] [Related]
3. Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.
Fletcher KA; Alkurashi MH; Lindsay AJ
Invest New Drugs; 2024 Feb; 42(1):14-23. PubMed ID: 37957513
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
[TBL] [Abstract] [Full Text] [Related]
5. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the her3/erbb3 receptor tyrosine kinase.
Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
[TBL] [Abstract] [Full Text] [Related]
6. AMT-562, a Novel her3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for her3-expressing Tumors.
Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
[TBL] [Abstract] [Full Text] [Related]
7. The circHMGCS1-miR-205-5p-erbb3 axis mediated the Sanggenon C-induced anti-proliferation effects on human prostate cancer.
Li J; Cao X; Chu T; Lin K; Chen L; Lv J; Tan Y; Chen M; Li M; Wang K; Zheng Q; Li D
Pharmacol Res; 2023 Jan; 187():106584. PubMed ID: 36462326
[TBL] [Abstract] [Full Text] [Related]
8. Whole-exome sequencing reveals a comprehensive germline mutation landscape and identifies twelve novel predisposition genes in Chinese prostate cancer patients.
Liang Y; Chiu PK; Zhu Y; Wong CY; Xiong Q; Wang L; Teoh JY; Cao Q; Wei Y; Ye DW; Tsui SK; Ng CF
PLoS Genet; 2022 Sep; 18(9):e1010373. PubMed ID: 36095024
[TBL] [Abstract] [Full Text] [Related]
9. Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer.
Li J; Wu H; Lv S; Quan D; Yang D; Xu J; Chen B; Ou B; Wu S; Wei Q
Pharmazie; 2022 Feb; 77(2):59-66. PubMed ID: 35209965
[No Abstract] [Full Text] [Related]
10. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type prostate cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract] [Full Text] [Related]
11. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
12. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer.
Lim SC; Geleta B; Maleki S; Richardson DR; Kovačević Ž
J Biol Chem; 2021 Dec; 297(6):101414. PubMed ID: 34785213
[TBL] [Abstract] [Full Text] [Related]
13. her3 Is an Actionable Target in Advanced prostate cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract] [Full Text] [Related]
14. Anti‑her3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
15. Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.
Wang J; Li Z; Yin F; Zhang R; Zhang Y; Wang Z; Sheng X
Cancer Gene Ther; 2022 Mar; 29(3-4):253-263. PubMed ID: 33742130
[TBL] [Abstract] [Full Text] [Related]
16. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
17. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
18. A structural view of PA2G4 isoforms with opposing functions in cancer.
Stevenson BW; Gorman MA; Koach J; Cheung BB; Marshall GM; Parker MW; Holien JK
J Biol Chem; 2020 Nov; 295(47):16100-16112. PubMed ID: 32952126
[TBL] [Abstract] [Full Text] [Related]
19. Microenvironment-Mediated Resistance to Anti-Androgen Therapy.
Orme JJ; Huang H
Cancer Cell; 2020 Aug; 38(2):155-157. PubMed ID: 32781041
[TBL] [Abstract] [Full Text] [Related]
20. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in prostate cancer.
Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL
Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108
[TBL] [Abstract] [Full Text] [Related]
[Next]